張偉娜 黃曉華

摘要：目的? 探討多西他賽聯(lián)合洛鉑腹腔灌注治療晚期卵巢癌患者的臨床療效。方法? 選取2017年4月～2018年4月我院收治的晚期卵巢癌患者中76例，隨機(jī)分為觀察組和對(duì)照組，每組38例。對(duì)照組僅接受多西他賽靜脈化療治療，觀察組接受多西他賽聯(lián)合洛鉑腹腔灌注治療。對(duì)比兩組臨床療效，并觀察治療后患者糖類多肽抗原（CA125）、血清人附睪分泌蛋白4（HE4）水平以及不良反應(yīng)發(fā)生情況。結(jié)果? 觀察組治療總有效率為97.37%，高于對(duì)照組的84.21%，差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。觀察組治療后CA125水平為（31.19±14.28）kU/L、HE4水平為（93.71±23.69）pmol/L，均低于對(duì)照組的（49.86±17.52）kU/L、（158.62±31.47）pmol/L，差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。觀察組總不良反應(yīng)發(fā)生率為13.16%，低于對(duì)照組的28.95%，差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論? 晚期卵巢癌患者接受多西他賽聯(lián)合洛鉑腹腔灌注治療效果更為理想，極大的改善了各功能指標(biāo)，降低了不良反應(yīng)發(fā)生率，臨床實(shí)用價(jià)值較高。

關(guān)鍵詞：多西他賽;洛鉑;腹腔灌注;晚期卵巢癌

中圖分類號(hào)：R737.31? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 文獻(xiàn)標(biāo)識(shí)碼：A? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?DOI：10.3969/j.issn.1006-1959.2019.08.047

文章編號(hào)：1006-1959（2019）08-0154-03

Abstract：Objective? To investigate the clinical efficacy of docetaxel combined with lobaplatin in the treatment of patients with advanced ovarian cancer. Methods? 76 patients with advanced ovarian cancer admitted to our hospital from April 2017 to April 2018 were randomly divided into observation group and control group， 38 cases in each group. The control group received only docetaxel intravenous chemotherapy， and the observation group received docetaxel plus lobaplatin intraperitoneal perfusion. The clinical efficacy of the two groups was compared， and the levels of carbohydrate polypeptide （CA125）， serum human epididymal secretory protein 4 （HE4） and adverse reactions were observed. Results? The total effective rate of the observation group was 97.37%， which was higher than that of the control group 84.21%，the difference was statistically significant （P<0.05）. The CA125 level of the observation group was （31.19±14.28） kU/L and the HE4 level was （93.71±23.69） pmol/L， which was lower than that of the control group （49.86±17.52） kU/L， （158.62±31.47） pmol/L， the difference was statistically significant （P<0.05）. The incidence of total adverse reactions was 13.16% in the observation group， which was lower than that in the control group 28.95%，the difference was statistically significant （P<0.05）. Conclusion? The treatment of patients with advanced ovarian cancer with docetaxel combined with lobaplatin is more ideal， which greatly improves the functional indicators， reduces the incidence of adverse reactions， and has higher clinical value.

Key words：Docetaxel;Lobaplatin;Intraperitoneal perfusion;Advanced ovarian cancer